New combo therapy aims to keep myeloma from coming back after transplant
NCT ID NCT01067287
First seen Apr 25, 2026 · Last updated Apr 29, 2026 · Updated 1 time
Summary
This study tested whether adding an experimental antibody (CT-011) and a personalized cancer vaccine after a stem cell transplant could help the immune system fight multiple myeloma and delay the cancer's return. 35 adults with multiple myeloma took part. The goal was to see if the combination was safe and boosted immune activity against the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02115, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Rambam Medical Center
Haifa, Israel
Conditions
Explore the condition pages connected to this study.